Payment overview · 2025
General Payments
$939.07
48 reported records · 18 companies
Healthcare provider profile · identity verified
Gary J Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NASHVILLE, TN · NPI 1659375228
Verified facts
What the public records show
CMS Open Payments records show Gary J Smith, M.D. received $939.07 in general payments during 2025 across 48 reported records.
Janssen Biotech, Inc. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $278.95 | 29.7% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.67 | 15.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.60 | 10.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.25 | 7.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.11 | 5.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.16 | 5.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.29 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.44 | 3.4% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $24.06 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.32 | 2.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.43 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.77 | 2.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $18.86 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.31 | 1.8% | 1 | 2025 |
| LNHC, Inc | Unresolved — no canonical attribution shown | $16.04 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.64 | 1.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.40 | 1.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.77 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $939.07 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $278.95 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.03 | 4 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $70.25 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.18 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.11 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.34 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| ZELSUVMI Normalized: zelsuvmi |
Drug | LNHC, Inc | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 102 |
| Lisinopril | Lisinopril | 309 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 244 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 75 |
| Alprazolam | Alprazolam | 225 | 48 |
| Gabapentin | Gabapentin | 203 | 41 |
| Metformin Hcl | Metformin Hcl | 202 | 60 |
| Azithromycin | Azithromycin | 190 | 142 |
| Meloxicam | Meloxicam | 176 | 43 |
| Omeprazole | Omeprazole | 176 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 39 |
| Trazodone Hcl | Trazodone Hcl | 143 | 35 |
| Furosemide | Furosemide | 141 | 51 |
| Lorazepam | Lorazepam | 141 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 41 |
| Simvastatin | Simvastatin | 110 | 32 |
| Eliquis | Apixaban | 108 | 15 |
| Losartan Potassium | Losartan Potassium | 105 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 35 |
| Tramadol Hcl | Tramadol Hcl | 103 | 21 |
| Diazepam | Diazepam | 100 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 19 |
| Methylprednisolone | Methylprednisolone | 89 | 78 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 22 |
| Carvedilol | Carvedilol | 83 | 20 |
| Metformin Hcl Er | Metformin Hcl | 83 | 26 |
| Sertraline Hcl | Sertraline Hcl | 82 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 27 |
| Atenolol | Atenolol | 71 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 15 |
| Farxiga | Dapagliflozin Propanediol | 70 | 18 |
| Famotidine | Famotidine | 66 | 14 |
| Pregabalin | Pregabalin | 64 | 13 |
| Valsartan | Valsartan | 63 | 21 |
| Candesartan Cilexetil | Candesartan Cilexetil | 61 | 15 |
| Allopurinol | Allopurinol | 60 | 13 |
| Promethazine Hcl | Promethazine Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 54 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 15 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 15 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 15 |
| Estradiol | Estradiol | 40 | 11 |
| Finasteride | Finasteride | 40 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 25 |
| Prednisone | Prednisone | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $939.07 · 48 records | Janssen Biotech, Inc. | ABRYSVO, AIRSUPRA, AUSTEDO XR, AZMIRO, BREZTRI, COMIRNATY, Cologuard Collection Kit, EBGLYSS, ELIQUIS, FARXIGA, Flector, JARDIANCE, KRYSTEXXA, Kerendia, Licart, MOUNJARO, NURTEC ODT, OPZELURA, Ozempic, PREVNAR 20, Quviviq, SKYRIZI, TALTZ, TREMFYA, Tirosint, VOQUEZNA, ZAVZPRET, ZELSUVMI, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error